Navigation Links
BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure
Date:3/11/2009

MINNEAPOLIS, March 11 /PRNewswire/ -- BridgePoint Medical, Inc.(TM), a leading medical technology company focused on the treatment of coronary and peripheral vascular disease, has completed the first human clinical case in the United States using its CrossBoss(TM) CTO Catheter and Stingray(TM) CTO Re-Entry System. The CrossBoss CTO Catheter and Stingray CTO Re-Entry System are under clinical investigation to demonstrate safety and effectiveness in the treatment of completely blocked arteries known as Chronic Total Occlusions (CTO). BridgePoint Medical's clinical trial, Facilitated Antegrade Steering Technique for Chronic Total Occlusions (FAST-CTOs), was conditionally approved in January 2009 by the FDA.

The first clinical case was completed by Dr. William Lombardi, Interventional Cardiologist and Cardiac Catheterization Lab Director at North Cascade Cardiology in Bellingham, Washington. The patient was a 61 year old woman with a chronic total occlusion of her right coronary artery, chest pain (characterized as level three angina) and a positive stress test. The patient was referred to Dr. Lombardi for inclusion in BridgePoint Medical's FAST-CTOs clinical trial after a failed treatment attempt to cross the lesion by a referring physician.

Procedural completion took 35 minutes, resulting in the opening of the completely blocked vessel and return of normal blood flow to the patient's heart. "The BridgePoint Medical System allowed me to open this challenging total occlusion," stated Dr. Lombardi. "BridgePoint Medical's clinical trial is designed to demonstrate the CrossBoss CTO Catheter and the Stingray Re-Entry System are broadly effective in re-establishing blood flow across completely blocked arteries and these devices will hopefully provide improved options for patient care." The patient was released from the hospital the day after the procedure.

Annually 1.3 million worldwide patients suffer from chronic total occlusions of coronary arteries. Interventional cardiologists are currently unable to broadly treat patients with chronic total occlusions, which comprise approximately one third of all patients diagnosed with coronary artery disease. For these patients, a common alternative is open heart bypass surgery or palliative medical care.

"We are very excited about the start of our United States clinical trial," said Chad Kugler, Co-Founder, President and General Manager of BridgePoint Medical. "We believe that our crossing systems will be demonstrated to provide a viable non-surgical alternative to this challenging form of heart disease."

About BridgePoint Medical

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.

www.bridgepointmedical.com


'/>"/>
SOURCE BridgePoint Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amy Street, Certified Prosthetist and Orthotist, Joins BridgePoint Medical Partner, Charlotte Orthotic and Prosthetic Center (COPC)
2. ASM Announces Seminars on Materials and Processes for Medical Devices
3. iVolution Medical Systems Acquires Professional Healthcare Billing Services
4. Medical Insurance Coverage in Africa a Possible Key to Improved Healthcare Access, States Frost & Sullivan
5. Kennedy Group Applies Its Packaging Expertise to Reusable Labeling in Handling Biomedical Waste Disposal
6. Devicor Medical Products Actively Seeking First Acquisition
7. Danube(TM) Technologies Jim Schiel to Share Scrum Best Practices Learned From Siemens Medical Solutions Project
8. Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project
9. Scorpion Offshore Inc. Pilot Project With InPlace Medical Solutions Sets New Standard for Offshore Medical Services
10. Quick Medical Posts Record Sales During Economic Downturn
11. Study finds pay for performance stimulates changes in medical practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: